Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Teijin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Teijin's 2013 immunology sales performance.

Pfizer/Opko's long-acting growth hormone misses mark in trial

Pfizer/Opko's long-acting growth hormone misses mark in trial

Also in the running is Versartis, whose somavaratan (VRS-317) is in late-stage trials and was recently licensed to Teijin in Japan.

Deal Watch August 2016

Deal Watch August 2016 252. Versartis. Teijin (JP). Licence Japan. Somavaratan, long-acting form of rhGH, for paediatric and adult growth hormone deficiency in phase II/III in Japan.

Teijin and Chugai to co-develop Ipsen's diabetes drug in Japan

Teijin had been developing ITM-077 alone and now expects to speed up the development and gain early regulatory approval with Chugai's help. ... Teijin and Chugai are now working together to establish a co-development plan.

1

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics